Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q5W0Q7
UPID:
USPL1_HUMAN
Alternative names:
Ubiquitin-specific peptidase-like protein 1
Alternative UPACC:
Q5W0Q7; Q14109; Q6AI45; Q8IY30; Q8IYE8
Background:
SUMO-specific isopeptidase USPL1, also known as Ubiquitin-specific peptidase-like protein 1, plays a pivotal role in protein desumoylation. It exhibits a high affinity for SUMO proteins, particularly SUMO2 and SUMO3, facilitating efficient cleavage. USPL1 is instrumental in RNA polymerase-II-mediated snRNA transcription within Cajal bodies and is a key component of complexes binding to U snRNA genes.
Therapeutic significance:
Understanding the role of SUMO-specific isopeptidase USPL1 could open doors to potential therapeutic strategies.